OTCMKTS:USRM Bioheart (USRM) Stock Price, News & Analysis $0.0001 0.00 (-50.00%) As of 07/2/2025 10:25 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesSEC FilingsBuy This Stock About Bioheart Stock (OTCMKTS:USRM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bioheart alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.0001▼$0.0002Volume123 shsAverage Volume105,955 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida. Read More Receive USRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioheart and its competitors with MarketBeat's FREE daily newsletter. Email Address USRM Stock News HeadlinesKennedy Says ‘Charlatans’ Are No Reason to Block Unproven Stem Cell TreatmentsJune 5, 2025 | nytimes.comThe Allure of Stem Cell TherapyJune 5, 2025 | nytimes.comBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.July 3 at 2:00 AM | Crypto 101 Media (Ad)How our bones are repaired by skeletal stem cells: Scientist discover four major subtypesJune 4, 2025 | msn.comFirst Stem Cell Nerve Therapy Meant to Reverse Paralysis Enters Clinical TrialMay 28, 2025 | msn.comVascularized stem cell islet organoids offer improved model for diabetes researchMay 23, 2025 | msn.comUltrasound and microrobots team up to boost stem cell therapy for brain repairApril 30, 2025 | msn.comNew approach targets cell surface protein to treat leukemia and solid tumorsApril 24, 2025 | msn.comSee More Headlines USRM Stock Analysis - Frequently Asked Questions How have USRM shares performed this year? Bioheart's stock was trading at $0.0001 at the beginning of the year. Since then, USRM shares have increased by 0.0% and is now trading at $0.0001. View the best growth stocks for 2025 here. How were Bioheart's earnings last quarter? Bioheart Inc. (OTCMKTS:USRM) released its quarterly earnings data on Wednesday, August, 7th. The company reported $0.00 EPS for the quarter. The business earned $1.30 million during the quarter. How do I buy shares of Bioheart? Shares of USRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bioheart own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bioheart investors own include Actinium Pharmaceuticals (ATNM), Cleveland BioLabs (CBLI), Cannabis Wheaton Income (CBWTF), Meta Platforms (META), Nextech3D.AI (NEXCF) and Orion Energy Systems (OESX). Company Calendar Last Earnings8/07/2019Today7/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBusiness Services Current SymbolOTCMKTS:USRM Previous SymbolNASDAQ:BHRT CIK1388319 Webwww.us-stemcell.com Phone(954) 835-1500Fax954-845-9976Employees11Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$80 thousand Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta-1.36 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:USRM) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioheart Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioheart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.